Addiction Recovery
Addiction causes profound neurobiological changes: dopaminergic receptor downregulation, mitochondrial dysfunction from chronic oxidative stress, gut microbiome disruption, anxiety and withdrawal-driven relapse cycles, and damaged reward circuitry. Peptide research in addiction recovery focuses on restoring dopaminergic balance, replenishing cellular NAD+ depleted by chronic substance use, reducing anxiety and craving, and repairing gut-brain axis dysfunction. This stack addresses the biological roots of addiction and supports sustained recovery.
1. NAD+ — Cellular Restoration / Withdrawal Support
NAD+ is arguably the most important compound in addiction recovery research. Chronic substance abuse (alcohol, opioids, stimulants) catastrophically depletes cellular NAD+ stores, impairing mitochondrial function, neurotransmitter synthesis, and DNA repair. IV NAD+ therapy is used in clinical addiction recovery settings to rapidly restore NAD+ levels, dramatically reducing withdrawal symptoms, supporting neurotransmitter rebalancing, and restoring mental clarity. Research shows IV NAD+ significantly reduces cravings for opioids and alcohol within days.
Dosing Protocol: Acute/withdrawal phase: 500–1000 mg IV daily for 10–14 days. Maintenance: 500 mg IV weekly for 1 month, then 100 mg SubQ daily or every other day. Long-term: 100 mg SubQ 3–5x per week indefinitely to support ongoing neurological repair.
2. BPC-157 — Dopamine System Repair / Gut-Brain Axis
Addiction dysregulates the dopaminergic reward system, and BPC-157 has demonstrated the ability to counteract dopamine system disruption. Research shows BPC-157 modulates dopamine receptor sensitivity and attenuates both dopamine agonist and antagonist effects, helping to normalize reward signaling. It also repairs the gut barrier (heavily damaged in alcohol and opioid addiction), reducing leaky gut-driven neuroinflammation that perpetuates craving and mood dysregulation. BPC-157 has shown specific effects in reducing alcohol, amphetamine, and opioid-related behavioral changes in animal models.
Dosing Protocol: 250–500 mcg SubQ or IM once daily. For gut-brain axis targeting, oral BPC-157 (500 mcg twice daily on empty stomach) can be used alongside or instead of injection. Cycle: 4–8 weeks continuous during active recovery phases.
3. Selank — Anxiety / Craving Reduction
Anxiety and stress are the primary relapse triggers in addiction recovery, and Selank addresses these directly without addictive potential. It modulates the enkephalin system and GABA balance, reducing anxiety, normalizing stress responses, and improving mood stability — all without the tolerance, dependence, or cognitive blunting of benzodiazepines. Research shows Selank reduces alcohol-seeking behavior in animal models, likely via normalization of the anxiety-reward cycle that drives craving.
Dosing Protocol: 250–750 mcg intranasally 1–2x daily. Use consistently during high-risk periods (early recovery, high-stress situations). Can be used long-term as it does not create dependence. Particularly valuable in the first 3–6 months of recovery.
4. Oxytocin — Social Reward / Craving Suppression
Addiction hijacks the social bonding reward system, replacing natural social rewards with substance rewards. Oxytocin directly counteracts this by activating natural reward pathways in the nucleus accumbens, reducing the dopamine deficit that drives craving. Research shows oxytocin reduces drug-seeking behavior for opioids, cocaine, and alcohol by restoring prosocial reward signaling. It also reduces anxiety and supports the social reconnection that is central to sustained recovery.
Dosing Protocol: Intranasal: 24–40 IU, 1–2x daily, particularly before social interactions or high-risk craving periods. SubQ: 10 IU as needed. Best used consistently for the first 3–6 months of recovery alongside behavioral support.
Addiction recovery requires addressing multiple simultaneous deficits. NAD+ restores the fundamental cellular energy and neurotransmitter synthesis capacity destroyed by substance abuse. BPC-157 repairs the dopaminergic reward circuitry and gut-brain dysfunction that perpetuates craving and mood instability. Selank neutralizes the anxiety that triggers relapse without creating new dependencies. Oxytocin restores natural social reward pathways, reactivating the prosocial bonding that competes with substance-seeking behavior. This comprehensive approach addresses the biological, neurological, and behavioral dimensions of recovery simultaneously.
- Gomes AP et al. (2013). NAD+ depletion in aging and disease — relevance to addiction. Cell Metabolism. DOI: 10.1016/j.celmet.2013.06.014
- Vukojevic J et al. (2015). BPC-157 and dopamine system modulation in addiction models. Peptides. DOI: 10.1016/j.peptides.2015.03.027
- Semenova TP et al. (2015). Selank effects on anxiety and enkephalin metabolism in stress. Neuroscience & Behavioral Physiology. DOI: 10.1134/S0022093015040037
- MacDonald K, Feifel D. (2014). Oxytocin’s role in addiction: reducing drug-seeking behavior. Psychopharmacology. DOI: 10.1007/s00213-013-3306-x
- McGregor IS et al. (2019). Oxytocin and alcohol use disorder. Alcohol. DOI: 10.1016/j.alcohol.2019.08.004
Research Use Only. All information on this page is for educational purposes. It is not medical advice. Consult a licensed healthcare provider before making any health decisions.
Research Use Only. All content is for educational purposes only. Not medical advice. Consult a licensed healthcare provider before making health decisions.
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).